We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioFocus and Usher III Initiative, Inc. Announce Collaboration

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFocus and Usher III Initiative, Inc. Announce Collaboration"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
BioFocus and the Usher III Initiative, Inc., a not-for-profit organization, announced that they have embarked on a drug discovery project focused on Usher Syndrome Type III.

Usher Syndrome is a rare genetic disorder that causes the loss of hearing and vision. Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.

“We are pleased to support the Usher III Initiative in its aim to find a targeted treatment and cure for Usher III,” said Angus MacLeod, Vice President, Medicinal Chemistry, BioFocus. “This collaboration will utilize BioFocus’ expertise in integrated drug discovery programs.”